Donanemab,an amyloid β-protein(Aβ)targeted monoclonal antibody,was approved for marketing by the Food and Drug Administration in July 2024.In contrast to other Aβ-targeted agents,donanemab specifically binds to the target Aβp3-42 amino-terminal pyroglutamate,thereby effectively clearing amyloid plaques from the brain.Studies have shown that donanemab can significantly slow down cognitive decline and disease progression in patients with early Alzheimer's disease.There are common adverse reactions including amyloid-related imaging abnormalities,infusion-related reactions,and drug allergies.
维普
万方数据